Fintel reports that on November 17, 2023, Citigroup upgraded its outlook for Larimar Therapeutics (NASDAQ:LRMR) from Neutral to to buy .
Analysis Price Forecast Suggests 283.66% Up
As of November 2, 2023, the average one-year price target for Larimar Therapeutics is 12.62. The forecasts range from a low of 4.54 to a high of $17.85. The average price target represents an increase of 283.66% from its last reported closing price of 3.29.
See our leaderboard of companies with the largest price target.
The projected annual revenue for Larimar Therapeutics is 0MM. The projected annual non-GAAP EPS is -1.64.
What is the Basic Sense?
There are 154 funds or institutions reporting positions in Larimar Therapeutics. This is an increase of 50 owner(s) or 48.08% in the last quarter. Average portfolio weight of all funds dedicated to LRMR is 0.06%, a decrease of 27.00%. Total shares owned by institutions increased in the last three months by 1.14% to 38,595K shares. LRMR’s put/call ratio is 0.04, indicating a bullish outlook.
What Are Other Shareholders Doing?
Deerfield Management Company, Lp holds 16,941K shares representing 38.59% ownership of the company. No change in the last quarter.
CHI Advisors holds 3,414K shares representing 7.78% ownership of the company. No change in the last quarter.
Verition Fund Management holds 2,901K shares representing 6.61% ownership of the company. In its previous filing, the company reported owning 2,717K shares, representing an increase of 6.34%. The company increased its portfolio allocation in LRMR by 14.36% during the last quarter.
Janus Henderson Group holds 2,461K shares representing 5.61% ownership of the company. In its previous filing, the company reported owning 1,446K shares, representing an increase of 41.27%. The company decreased its portfolio allocation in LRMR by 19.61% during the last quarter.
Citadel Advisors holds 979K shares representing 2.23% ownership of the company. In its previous filing, the company reported owning 1,177K shares, representing decline of 20.17%. The company increased its portfolio allocation in LRMR by 8.90% during the last quarter.
Larimar Therapeutics Background Information
(This description is provided by the company.)
Larimar Therapeutics, Inc., is a clinical-stage biotechnology company focused on developing therapies for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in the United States as a potential therapy for FA. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Fintel is one of the most comprehensive investment research platforms available for individual investors, traders, financial advisors and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fundamental sentiment, option sentiment, insider trading, option flow, unusual options trades and much more. Additionally, our exclusive stock options are powered by advanced, back-tested quantitative models for enhanced returns.
Click to Learn More
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.